Baird served as a co-manager on this transaction
AboutEndocyte, Inc. (“Endocyte” or the “Company”) (NASDAQ-GS: ECYT) recently completed a follow-on offering of 5,175,000 shares of common stock at a price of $21.00 per share, generating gross proceeds of $108.7 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including without limitation research and development expenses such as clinical trial costs, capital expenditures and general and administrative expenses.
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The Company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. The Company is headquartered in West Lafayette, Indiana.
For additional information about this transaction, please contact:
- April 2014
- Endocyte, Inc.
- Target Geography
- North America